Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Heather Dawn Brooks
Observed names:
H. D. Brooks,
H.D. Brooks,
Heather Brooks,
Heather D. Brooks
Institution:
The US Oncology Network
Observed institutions:
The University of Texas MD Anderson Cancer Center,
University of Virginia Health System,
The US Oncology Network,
University of Virginia
OpenAlex ID:
A5081795255
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma
2010
·
Heather D. Brooks
, Bonnie S. Glisson
, et al.
·
Cancer
·
122
PDF
Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
2016
·
Jeff P. Sharman
, Charles M. Farber
, et al.
·
British Journal of Haematology
·
70
PDF
Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
2017
·
David Jacob Andorsky
, Abdulraheem Yacoub
, et al.
·
Journal of Clinical Oncology
·
22
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
2014
·
Jeff P. Sharman
, Charles M. Farber
, et al.
·
Blood
·
17
Isolated Polyarticular Septic Arthritis: An Atypical Presentation of Meningococcal Infection
2008
·
Michael Mcculloch
, Heather Brooks
, et al.
·
The American Journal of the Medical Sciences
·
17
MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
2016
·
David J. Andorsky
, Abdulraheem Yacoub
, et al.
·
Blood
·
12
Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC)
2009
·
H. D. Brooks
, B. Glisson
, et al.
·
Journal of Clinical Oncology
·
12
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
2015
·
Kathryn Kolibaba
, John M. Burke
, et al.
·
Blood
·
8
Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
2018
·
David Andorsky
, Morton Coleman
, et al.
·
Journal of Clinical Oncology
·
6
Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma
2017
·
M. Coleman
, D.J. Andorsky
, et al.
·
Hematological Oncology
·
6
PDF
Evolving Treatment Paradigms in Non-Small Cell Lung Cancer
2012
·
Kathryn F. Mileham
, Heather D. Brooks
, et al.
·
1
LMO2 and Bcl-6 Expression in Diffuse Large B-Cell Lymphoma Predict Overall Survival in R-CHOP Treated Patients
2008
·
Heather D. Brooks
, Robert M. Graham
, et al.
·
Blood
·
1
Effectiveness of a dedicated therapist on improving prospective identification and pre-operative rehabilitation (PREHAB) to reduce post-operative treatment encounters for breast cancer-related lymphedema (BCRL) in a rural and underserved population.
2023
·
Tara Newberry
, Betty Abrahamsen
, et al.
·
JCO Oncology Practice
Show more works
View as search
Works count:
13
Citation count:
294
H-index:
8
I10-index:
7
Year
Topic
Type